Advertisement

Diabetology International

, Volume 6, Issue 2, pp 104–116 | Cite as

Efficacy and safety of ipragliflozin as an add-on to pioglitazone in Japanese patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study (the SPOTLIGHT study)

  • Atsunori Kashiwagi
  • Takanori Shiga
  • Noriko Akiyama
  • Kenichi Kazuta
  • Atsushi Utsuno
  • Satoshi Yoshida
  • Eiji Ueyama
Original Article

Abstract

Ipragliflozin is a novel oral sodium–glucose cotransporter 2 (SGLT2) inhibitor under development for the treatment of type 2 diabetes. We examined its efficacy and safety as an add-on to pioglitazone in Japanese patients with inadequately controlled diabetes. Japanese type 2 diabetes patients were randomized to 24 weeks of treatment with 50 mg ipragliflozin or placebo in a double-blind manner. At week 24, patients with hemoglobin (Hb)A1c <8.4 % were permitted to continue open-label ipragliflozin in a 28-week extension period. The primary endpoint was the change in HbA1c from baseline to week 24 (with last observation carried forward). Ninety-eight and 54 patients were randomized to ipragliflozin or placebo, respectively, and were prescribed the study drug. The mean HbA1c change from baseline to week 24 was −0.64 % and 0.22 % in the ipragliflozin and placebo groups, respectively, and the adjusted mean difference between the two groups was −0.88 % (P < 0.001). Changes in fasting plasma glucose (FPG) and body weight were significantly greater in the ipragliflozin group (both P < 0.001). Among patients who continued ipragliflozin in the extension period, reductions in HbA1c, FPG, and body weight were maintained until week 52. The incidence of treatment-emergent adverse events was not significantly different between the two groups. The most common event with a higher incidence in the ipragliflozin group than in the placebo group was pollakiuria (12/97 vs. 0/54 patients). Ipragliflozin improved glycemic control, promoted weight reduction, and had a good safety profile as an add-on to pioglitazone in Japanese type 2 diabetes patients.

Keywords

Ipragliflozin Japanese Pioglitazone Randomized controlled trial SGLT2 Type 2 diabetes 

Notes

Acknowledgments

Ipragliflozin is under development by Astellas Pharma Inc. and Kotobuki Pharmaceutical Co., Ltd. This study was sponsored by Astellas Pharma Inc. Medical writing and editorial support was funded by Astellas Pharma Inc., and was provided by Dr. Nicholas D. Smith and ELMCOM™.

Conflict of interest

TS, NA, KK, AU, SY, and EU are employees of Astellas Pharma Inc. AK has acted as a consultant for Astellas Pharma Inc. and has received consulting fees/honoraria from Astellas Pharma Inc.

References

  1. 1.
    Sabolić I, Vrhovac I, Eror DB, Gerasimova M, Rose M, Breljak D, Ljubojević M, Brzica H, Sebastiani A, Thal SC, Sauvant C, Kipp H, Vallon V, Koepsell H. Expression of Na+-d-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences. Am J Physiol Cell Physiol. 2012;302:C1174–88.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009;75:1272–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab. 2010;95:34–42.PubMedCrossRefGoogle Scholar
  4. 4.
    Kadokura T, Saito M, Utsuno A, Kazuta K, Yoshida S, Kawasaki S, Nagase I, Kageyama S. Ipragliflozin (ASP1941), a selective sodium-dependent glucose cotransporter 2 inhibitor, safely stimulates urinary glucose excretion without inducing hypoglycemia in healthy Japanese subjects. Diabetol Int. 2011;2:172–82.CrossRefGoogle Scholar
  5. 5.
    Veltkamp SA, Kadokura T, Krauwinkel WJ, Smulders RA. Effect of ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects. Clin Drug Investig. 2011;31:839–51.PubMedCrossRefGoogle Scholar
  6. 6.
    Schwartz SL, Akinlade B, Klasen S, Kowalski D, Zhang W, Wilpshaar W. Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2011;13:1219–27.PubMedCrossRefGoogle Scholar
  7. 7.
    Fonseca VA, Ferrannini E, Wilding JP, Wilpshaar W, Dhanjal P, Ball G, Klasen S. Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. J Diabetes Complicat. 2013;27:268–73.PubMedCrossRefGoogle Scholar
  8. 8.
    Kashiwagi A, Kazuta K, Yoshida S, Nagase I. Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig. 2013;. doi: 10.1111/jdi.12156.Google Scholar
  9. 9.
    Wilding JP, Ferrannini E, Fonseca VA, Wilpshaar W, Dhanjal P, Houzer A. Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. Diabetes Obes Metab. 2013;15:403–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–79.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf. 2009;32:187–202.PubMedCrossRefGoogle Scholar
  12. 12.
    Smulders RA, Zhang W, Veltkamp SA, van Dijk J, Krauwinkel WJ, Keirns J, Kadokura T. No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. Diabetes Obes Metab. 2012;14:937–43.PubMedCrossRefGoogle Scholar
  13. 13.
    Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.PubMedCrossRefGoogle Scholar
  14. 14.
    Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, Ito H, Tominaga M, Oikawa S, Noda M, Kawamura T, Sanke T, Namba M, Hashiramoto M, Sasahara T, Nishio Y, Kuwa K, Ueki K, Takei I, Umemoto M, Murakami M, Yamakado M, Yatomi Y, Ohashi H. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Diabetol Int. 2012;3:8–10.CrossRefGoogle Scholar
  15. 15.
    Director, Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. Guideline for clinical evaluation of oral hypoglycemic agents. Tokyo: Ministry of Health, Labour and Welfare; 2010.Google Scholar
  16. 16.
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012;35:1473–8.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013;11:43.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011;13:928–38.PubMedCrossRefGoogle Scholar
  20. 20.
    Bolinder J, Ljunggren Ö, Kullberg J, Johansson L, Wilding J, Langkilde AM, Sugg J, Parikh S. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020–31.PubMedCrossRefGoogle Scholar
  21. 21.
    Campbell IW. Comparing the actions of older and newer therapies on body weight: to what extent should these effects guide the selection of antidiabetic therapy? Int J Clin Pract. 2010;64:791–801.PubMedCrossRefGoogle Scholar
  22. 22.
    Kaku K, Inoue S, Matsuoka O, Kiyosue A, Azuma H, Hayashi N, Tokudome T, Langkilde AM, Parikh S. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2013;15:432–40.PubMedCrossRefGoogle Scholar

Copyright information

© The Japan Diabetes Society 2014

Authors and Affiliations

  • Atsunori Kashiwagi
    • 1
  • Takanori Shiga
    • 2
  • Noriko Akiyama
    • 2
  • Kenichi Kazuta
    • 2
  • Atsushi Utsuno
    • 2
  • Satoshi Yoshida
    • 2
  • Eiji Ueyama
    • 2
  1. 1.Shiga University of Medical ScienceShigaJapan
  2. 2.Astellas Pharma IncTokyoJapan

Personalised recommendations